Leukemia

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.

High rates of hematopoietic cell transplantation were observed in patients with relapsed/refractory acute myeloid leukemia who received 131-iodine conditioning in the phase 3 SIERRA trial.

Patients with previously untreated IDH1-mutant acute myeloid leukemia experienced significant clinical benefit following treatment with ivosidenib and azacitidine compared with the placebo combination.

TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

In an interview with CancerNetwork®, Paul Barr, MD, discusses 8-year follow-up data from the phase 3 RESONATE-2 trial, assessing first-line ibrutinib in patients 65 years of age or older with chronic lymphocytic leukemia.

The FDA has lifted its partial clinical hold on magrolimab and azacitidine studies for patients with acute myeloid leukemia and myelodysplastic syndrome.

Investigators uncovered potential mechanisms of resistance to CD19-directed CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia.

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

Longer and more durable remissions were identified with the addition of CART-19 to ibrutinib for patients with chronic lymphocytic leukemia.

In an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.

The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.

Based on results from a phase 1 trial, the FDA has granted fast track designation to PRGN-3006 UltraCAR-Tin relapsed/refractory acute myeloid leukemia.

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Pediatric patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma experienced an improvement in survival following treatment with bortezomib and chemotherapy.

A supplemental new drug application for ivosidenib plus azacitidine was granted priority review by the FDA for previously untreated patients with IDH1-mutant acute myeloid leukemia.

Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment with a hypomethylating agent plus venetoclax followed by hematopoietic stem cell transplant could improve outcomes in patients with treated secondary acute myeloid leukemia.

New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.

The FDA has granted IO-202, a LILRB4 checkpoint inhibitor, fast track designation for the treatment of relapsed or refractory acute myeloid leukemia.

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19, according to a prospective study.

Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.

The FDA has placed a partial clinical hold on trials using umbralisib and ublituximab as a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

BNT200 is a device designed to treat anxiety and depressive symptoms in adults with acute myeloid leukemia.

Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

An upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.

The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.

Patients with chronic lymphocytic leukemia treated with fixed duration venetoclax/rituximab may experience prolonged disease control vs bendamustine/rituximab.

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Two-year overall survival increased from period between 2000 and 2004 to period between 2015 and 2019 for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation.